Our Team
Senior Team
Ned Wakeman
CEO
Scientist with entrepreneurial/ investment banking background. Raised \>£600m for VC funds/SMEs (including ophthalmology). Director Alderley Park Accelerator, supporting ~250 companies. Founder of Lean Life Science Oncology Development Programme, with over 40 industry partners, and 100 Experts. Extensive experience of funding/de-risking_SMEs.
Kevin Pritchard
CSO
Former Head Protein Science AstraZeneca, previously Cambridge-Antibody Technology. 19+years in complex protein design/development.
Chris Doherty
Chair of SAB
Former VP/Head Pharmaceutical Development, AstraZeneca. 30+years in formulation leadership roles across the pharma industry.
Stephen From
Chairman
M&A Banker, CEO Eyegate Pharma leading them from VC-to-IPO developing technologies for treating eye_diseases, multiple pharma_licensing deals.
Alys Davies
Principal Scientist
Biomaterials Scientist 8+ years in ophthalmic drug delivery. Has designed/developed in vitro/in vivo/in silico models of drug delivery for retinal disease.
Joe de Souza
Project Mgmt
27+years AstraZeneca Senior R&D Project/Line Leadership. PRINCE2-Accredited
Paul Gellert
Formulation
33+years Drug_Development AstraZeneca, specialising in novel formulation design/delivery.
David Jones
Regulatory
Lab Team
Alys Davies PhD
Principal Scientist
Biomaterials Scientist 8+ years in ophthalmic drug delivery. Has designed/developed in vitro/in vivo/in silico models of drug delivery for retinal disease.
Deepak Mishra PhD
Associate Principal Scientist
Medicinal and Pharmaceutical Chemist with 6+years specialising in ocular drug delivery and formulation development.
Bryony Warren-Brown
Senior Scientist
Masters qualified, lab-based team members with expertise in a range of chemical/biochemical techniques and extensive hands-on experience of peptide hydrogels.
Scott Hardy
Research Scientist
Masters qualified, lab-based team members with expertise in a range of chemical/biochemical techniques and extensive hands-on experience of peptide hydrogels.